Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aesica Partners with the University of Nottingham

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
Latest Aesica Innovation Board (AIB) initiative to increase yields and reduce costs of production.

Aesica has announced a partnership with the University of Nottingham for the commercial development of alternative methods in amide bond synthesis.

This latest partnership is already the Aesica Innovation Board’s (AIB) fourth with an academic institution in less than six months; having been established to help bridge the growing R&D gap by identifying early stage technologies for development into commercial applications.

Amide bond formation is fundamental in pharmaceutical manufacturing. A recent survey conducted by the Green Chemistry Institute Roundtable identified that amide bond formation was utilized in 84 % of a set of drug candidates.

The partnership’s aim is to revolutionize traditional amide formation techniques by generating alternative methods for amide bond formation, which will be more eco-friendly and chemically versatile.

This innovative approach will be commercially available to Aesica customers in the next two to three months and already the company is actively seeking commercial opportunities to work with potential compounds that could benefit from this novel technology.

Aesica envisages this new development helping pharmaceutical companies encountering problems with amide synthesis, and due to the utilization of more sustainable reagents, production costs will be lowered, whilst offering the potential of higher chemical yields.

The University of Nottingham has a strong track record of world-leading research in Green and Sustainable Chemistry. This collaboration builds upon recently announced plans to establish a Centre of Excellence for Sustainable Chemistry, part-funded by an investment from the Higher Education Funding Council for England (HEFCE) UK Research Partnership Investment Fund.

The Centre aims to form creative partnerships with innovative companies like Aesica to develop new chemical based technologies that minimize environmental impact and are both energy and resource efficient.

The University was confident about the success of this technology on a small-scale basis and was keen to test its robustness in a commercial application.

Preliminary studies were undertaken using funds awarded by the Engineering and Physical Sciences Research Council (EPSRC) under the Research Development (Pathways to Impact) Funding Scheme.

Aesica has been quick to forge ahead with an increasing number of academic partnerships and this collaboration is yet another example of the changing way in which the most innovative university research techniques are being harnessed and applied by industry for commercial solutions.

“Since realizing the initial use of our coupling agent in 2005, one of our goals has been to see this novel technology used in larger scale industrial environments. We look forward to collaborating with Aesica and seeing the full commercial potential of this novel technology in API manufacture.” Simon Woodward, Professor of Synthetic Organic Chemistry, University of Nottingham.

"Aesica is delighted to be partnering with a renowned institution like the University of Nottingham and Prof. Simon Woodward. This new amide production technology is hugely exciting, and ultimately, this will enable cheaper and simpler routes to market for many compounds. Professor Woodward's ability to carry out high calibre research coupled with our desire to bring new economically important and innovative technologies to the market is the basis for a truly collaborative partnership". Barrie Rhodes, Director of Technology Development, Aesica Pharmaceuticals.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica and The University of Nottingham Collaborate
The partnership will explore the development of alternative methods in amide bond synthesis.
Wednesday, May 08, 2013
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!